Diagonal Bio publishes the Annual Report for 2024
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today publishes the Company’s annual report for 2024. The annual report in Swedish and available as an attached file to this release and is also available on Diagonal Bio’s website.
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.